This company listing is no longer active
7DQ Stock Overview
European Biotech Acquisition Corp. does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
European Biotech Acquisition Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.20 |
| 52 Week High | US$11.00 |
| 52 Week Low | US$8.45 |
| Beta | 0 |
| 1 Month Change | 12.71% |
| 3 Month Change | 8.51% |
| 1 Year Change | 17.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 26.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7DQ | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | 13.3% | -0.8% | -2.0% |
| 1Y | 17.2% | 17.8% | -0.3% |
Return vs Industry: 7DQ exceeded the German Capital Markets industry which returned 5.9% over the past year.
Return vs Market: 7DQ exceeded the German Market which returned -6.2% over the past year.
Price Volatility
| 7DQ volatility | |
|---|---|
| 7DQ Average Weekly Movement | 4.8% |
| Capital Markets Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7DQ has not had significant price volatility in the past 3 months.
Volatility Over Time: 7DQ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Eduardo Bravo de Araoz | www.lspvc.com/ebac |
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on business in the life sciences industry in Europe.
European Biotech Acquisition Corp. Fundamentals Summary
| 7DQ fundamental statistics | |
|---|---|
| Market cap | €173.13m |
| Earnings (TTM) | €811.86k |
| Revenue (TTM) | n/a |
213.3x
P/E Ratio0.0x
P/S RatioIs 7DQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7DQ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$860.48k |
| Earnings | US$860.48k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.052 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7DQ perform over the long term?
See historical performance and comparison